Publications
New IgAN papers, screened for relevance and ranked. The top items get a short note on why they matter.
For Medical Affairs · IgA nephropathy
Stay current on IgA nephropathy in one read every other Thursday
New papers, trial registry changes, preprints and regulatory news, ranked by clinical importance. Every item links to its source.
Thanks, you're almost on the list. Check your inbox for a confirmation email from Buttondown and click the link in it. If you don't see it in a few minutes, look in your spam or promotions folder.
Free to join. $14.99/month when it opens. Read a full sample issue.
IgA Nephropathy Brief · Issue 04
Window: Sep 11 to 24, 2026
19Papers
10Trials updated
3New trials
1Ph3 topline
1
Sefaxersen meets Phase 3 IMAGINATION primary endpoint
Roche reported a significant proteinuria reduction at Week 37 (n=459) but held back the effect size. First antisense readout in IgAN.
Topline Sep 23 · NCT05797610
2
SPARTAN: sparsentan as first-line therapy
Moves the dual endothelin/angiotensin blocker from add-on toward first line, with 12-month real-world data alongside.
Kidney Int Rep · doi:10.1016/j.ekir.2026.107105
5
First Gd-IgA1-guided treatment-selection RCT registered
Peking University (n=374). Separately, argenx starts a Phase 2 of ARGX-121 in IgAN.
NCT07822100 · NCT07773727
Sources we search:
PubMed
Crossref
ClinicalTrials.gov
bioRxiv · medRxiv
Research Square
FDA · EMA · company news
The problem
Keeping up with one disease area takes hours you don't have
Saved PubMed searches return hundreds of hits. Trial records change without notice. Preprints show up months before the journal version. In many Medical Affairs teams, one person pulls it together by hand.
Large pharma companies pay for enterprise intelligence platforms. If you work at a small or mid-size biotech, or on your own, you usually do it yourself.
What you get
Four sources, one brief
Clinical trials
New registrations and changed records on ClinicalTrials.gov: status, enrollment, phase and sponsor.
Preprints
Early work from bioRxiv, medRxiv and Research Square, often months ahead of the journal.
Regulatory and toplines
Approvals, PDUFA dates and company topline announcements that touch the indication.
How it works
Wide search, careful filtering, sources attached
Search wide
Every two weeks we pull everything new in the window from each source, using a broad set of IgAN terms and synonyms.
Screen and rank
An AI model sorts each item as relevant, borderline or off-topic, then ranks what's left by how much it could change practice or strategy.
Show the work
Each item keeps its DOI or NCT number. The footer lists the searches, dates and any source that failed.
Track record
What we've measured so far
4issues published since August 2026
26/26relevant papers caught in our first full completeness test (Aug 28 to Sep 10)
30/35caught by the earlier search version (86%). We fixed the terms and retested.
3 of 4issues ran with a source offline, and said so at the top
What we tell you when something goes wrong
When a source is down, the issue opens with a note that names it and says what might be missing. After Issue 03 ran without PubMed, we reran the full search and printed the missed papers in Issue 04.
One completeness test is a small sample. We will publish more results as we run them.
Options
How it compares
| Doing it yourself | Enterprise CI platforms | Outsourced CI firms | Sentinel | |
|---|---|---|---|---|
| Cost | Your time | Annual contracts, pricing on request | Priced for companies | $14.99/month |
| Your time each fortnight | Hours | Setup plus ongoing searching | Briefing calls and reviews | One read |
| Trials and preprints included | Only if you check them | Usually | Usually | Yes |
| Every item linked to its source | Yes | Varies | Varies | Yes |
| Built for | Anyone | Large teams | Companies | Individuals and small teams |
Pricing
One price per disease area
$14.99 / month per indication
- A new brief every other Thursday
- Publications, trials, preprints and regulatory news
- Every item linked to its source
- Search method and source status included
- Cancel any time
Starting with IgA nephropathy. We'll add other diseases based on what waitlist members ask for.
Join the waitlist
No payment now. When subscriptions open, we'll send you the latest issue and an invitation to subscribe.
Thanks, you're almost on the list. Check your inbox for a confirmation email from Buttondown and click the link in it. If you don't see it in a few minutes, look in your spam or promotions folder.
By joining you agree to receive emails about TherapyArea Sentinel. Unsubscribe any time. See our privacy note.
Questions
Frequently asked questions
Who writes the brief?
An AI system finds, screens and summarizes each issue. A human owner sets the rules and scope. No editor reads each issue before it goes out, which is why every item links to its source so you can check it.
Which sources do you check?
PubMed, Crossref, ClinicalTrials.gov, preprint servers (bioRxiv, medRxiv, Research Square) and public regulatory and company news. If a source is unavailable for an issue, the issue says so at the top.
How complete is it?
We test it. In our first full benchmark (Aug 28 to Sep 10, 2026) the brief caught 26 of 26 relevant IgA nephropathy papers found by a broader reference search. An earlier version of the search caught 30 of 35 (86%) on an August window; we fixed the search terms and tested again. One test is a small sample.
Can I use it for pharmacovigilance literature screening?
No. It is not validated for regulated pharmacovigilance or GVP literature screening and has no audited process. Use it for awareness and planning.
What do I pay now?
Nothing. The waitlist is free. When subscriptions open, the price is $14.99 per month per indication and you can cancel at any time.
Will you cover other diseases?
Possibly. IgA nephropathy is first. Tell us your indication when you join the waitlist; demand decides what comes next.